John Oyler Sells 61,397 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 61,397 shares of the business’s stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $317.67, for a total value of $19,503,984.99. Following the transaction, the chief executive officer directly owned 9,180 shares in the company, valued at $2,916,210.60. This trade represents a 86.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The stock was sold at an average price of $312.25, for a total value of $15,086,671.00.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Up 0.7%

BeOne Medicines stock traded up $2.12 during trading hours on Tuesday, hitting $328.02. 92,531 shares of the stock traded hands, compared to its average volume of 278,183. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $253.95 and a one year high of $385.22. The firm’s 50-day moving average price is $292.10 and its two-hundred day moving average price is $309.39. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The company has a market cap of $35.99 billion, a PE ratio of 73.35 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current year.

Institutional Investors Weigh In On BeOne Medicines

Hedge funds have recently added to or reduced their stakes in the stock. EFG International AG bought a new position in shares of BeOne Medicines during the fourth quarter valued at $25,000. Leonteq Securities AG purchased a new position in shares of BeOne Medicines in the 4th quarter worth about $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines in the 2nd quarter worth about $35,000. CWM LLC boosted its stake in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares in the last quarter. Finally, Group One Trading LLC purchased a new stake in BeOne Medicines during the 4th quarter valued at about $61,000. 48.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on ONC. Citizens Jmp reiterated a “market outperform” rating and issued a $396.00 price objective on shares of BeOne Medicines in a report on Wednesday, July 1st. Morgan Stanley reaffirmed an “overweight” rating and issued a $395.00 target price on shares of BeOne Medicines in a research report on Thursday, May 7th. Truist Financial increased their price target on shares of BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $394.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.